Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer

Inclusion Criteria: * Patients must have histologically confirmed advanced, prostate cancer * Patients must have evaluable disease that may be evaluated by PSA or measurement. * Patients must be hormone refractory as defined in this protocol. * Patients must be taxane refractory as defined in this protocol. * Patients have had no prior chemotherapy other than a taxane or estramustine phosphate. * Patients may have had prior radiation therapy (RT) if it has been \>/= 4 weeks since completion. * Patients on bisphosphonates may be included. * Patients must be at least 18 years of age or older. * Patients must have the ability to speak and understand English. * Patients must have an ECOG performance status of 2 or less. * Patients must have adequate bone marrow function: platelets \> 100,000 cells/mm3; hemoglobin \> 9.0 g/dL; and absolute neutrophil count (ANC) \> 1,000 cells/mm3. * Patients must have adequate renal function: creatinine \< 2.5 mg/dL. * Patients must have adequate liver function. * Ejection fraction of \> 50% within 42 days of first dose of study drug. * Ability to complete the McGill-Melzack Pain Intensity Scale. Exclusion Criteria: * Patients with unstable medical conditions such as liver, renal dysfunctions, blood clots or heart disease. * History of hypersensitivity to doxorubicin. * History of class II cardiac disease or evidence of congestive heart failure. * RT within the past 4 weeks of study entry or a radiopharmaceutical within the past 8 weeks of study entry. * Prior malignancy within the past 5 years except for non-melanotic skin cancers.